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Triple H (hypertension, hyperlipidemia,
hyperglycemia) and stroke
Abstract
Stroke is the third most frequent cause of death worldwide and the most
frequent cause of permanent disability. Modification of lifestyle and risk
factors treatment in the world has led to the reduction of stroke incidence
and mortality of stroke. The economic burden is tremendous as well as
influence on private and social life, since many patients require chronic care
and long-term institutionalization. Stroke prevention begins with recogni-
tion of its risk factors by a patient and clinicians treating the patient, most
patients having a stroke have multiple risk factors therefore it are of great
importance to recognize all of the stroke risk factors and to educate the
patient and the family how to control them.
INTRODUCTION
Stroke risk factors have been classified as traditional and novel (hy-perhomocysteinemia, hypercoagulable states, and select biomarkers),
and modifiable and nonmodifiable. Risk factors for cerebrovascular
disease are non modifiable risk factors: age, gender, race/ethnic, geno-
type, previous myocardial infarction, TIA or stroke and modifiable risk
factors: diabetes, hyperlipidemia, arterial hypertension, atrial fibrilla-
tion, coronary and or peripheral artery disease, obesity, physical inac-
tivity, stress, alcohol consumption, and smoking (1–4).
In order of better and faster evaluation of stroke risk factors the Fra-
mingham Stroke Risk Profile (FSRP) was developed. Authors of the FSRP
were using data from 36 years follow up in the Framingham cohort and
has been validated in other cohorts. The FSRP provides sex specific
estimation of the probability of stroke using clinical information.
Atherosclerosis is a central pathomorphological mechanism which
leads to narrowing of arterial walls throughout the body as well in brain
causing cerebrovascular disease. Atherosclerosis is thought to be result
from chronic inflammation and injury to the arterial wall in the peri-
pheral or coronary vascular system. In response to endothelial injury
and inflammation, oxidized lipids from LDL (low density lipoproteins)
particles accumulate in the endothelial part of the vessel wall. Angio-
tensin II may promote the oxidation of such particles. Monocyte than
infiltrate the arterial wall and differentiate into macrophages, which
accumulate oxidized lipids to form foam cells. Once formed, foam cells
stimulate macrophage proliferation and attraction of T-lymphocytes.
T-lymphocytes in turn, induce smooth muscle proliferation in the









Iris Zavoreo, MD, PhD, Ass. Professor






Key words: stroke, hypertension,
hyperlipidemia, hyperglicemia
Received September 20, 2012.
PERIODICUM BIOLOGORUM UDC 57:61
VOL. 114, No 3, 269–275, 2012 CODEN PDBIAD
ISSN 0031-5362
overview
is the formation of a lipid-rich atherosclerotic lesion with
a fibrous cap. Rupture of this lesion leads to acute vascu-
lar infarction, this ruptures and bleeding into the plaque
are more frequent in diabetic patients (diabetic patients
have higher perioperative risk for carotid endarcterec-
tomy as well). In addition to atheroma formation, there is
a strong evidence of increased platelet adhesion, hyper-
coagulability, impaired nitric oxide generation and in-
creased free radical formation as well as altered calcium
regulation in diabetic patients (1, 5).
Hypertension, hyperglycemia and hyperlipidaemia are
most prevalent modifiable risk factors.
Hypertension
Hypertension is the most prevalent modifiable risk
factor for stroke with a prevalence of about 30% in mo-
dern western countries. The prevalence of hypertension
increases with age,
The Framingham Heart Study investigators reported
the lifetime risk of hypertension to be approximately 90%
for men and women who were non-hypertensive at age
55 or 65 years and survived to ages 80–85 years old. A
meta-analysis of one million adults enrolled in 61 obser-
vational studies concluded that death from ischemic heart
disease and stroke increases
Progressively and linearly with systolic blood pressure
levels as low as 115 mm Hg and diastolic 75 mm Hg
upward. This study also found that for every 20 mm Hg
systolic or 10 mm Hg diastolic increase in blood pressure
there is a doubling of mortality from both ischemic heart
disease and stroke. The authors suggest a 10 mm Hg
reduction in systolic or a 5 mm Hg reduction in diastolic
blood pressure would result in a 40% lower risk of stroke
death and a 30% lower risk of death from ischemic heart
disease or other vascular death (5–7).
The United Kingdom-transient ischemic attack (TIA)
trial evaluated blood pressure and risk of stroke in pa-
tients with diagnosed cerebrovascular disease and found
a direct and continuous relationship between blood pres-
sure and recurrent strokes. Their data demonstrated that
a 5mm Hg lower diastolic blood pressure was associated
with reduction of stroke for about one third (8). Based on
data such as these the 2003 Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC-7) redefined the classification of
hypertension. In the new classification, blood pressure
<120/80 mm Hg was changed from »optimal« to »nor-
mal« and the new term »prehypertension« was used for a
systolic blood pressure of 120–139 mm Hg and/or dia-
stolic blood pressure of 80–89 mm Hg. The aim of this
reclassification was to encourage lifestyle changes at early
stages of hypertension, and reduce the incidence of stroke
and heart attack. Lifestyle change includes diet, mainly
eating more fruits and vegetables (meta analysis of 9
independent studies has shown that 3–5 servings per day
reduces risk for stroke for 0,89) and consuming less salt, in
addition to weight loss, aerobic activity and moderation of
alcohol consumption. Pharmacological treatment is not
recommended until systolic pressures exceed 140 mm
Hg or diastolic exceeds 90 mm Hg (brain perfusion).
Whereas the necessity to treat hypertension to reduce the
risk of cerebrovascular events is clear, there is less clarity
regarding the best choice of antihypertensive medication.
The Heart Outcomes Prevention Evaluation (HOPE)
Study demonstrated improved cardiovascular outcomes
with the use of the angiotensinconverting enzyme inhi-
bitor (ACEI) ramipril beyond its ability to lower blood
pressure, which was very mild in this trial (the average
reduction of systolic/diastolic blood pressure was 3/2 mm
Hg) (9). Subsequently, the Losartan Intervention for
Endpoint reduction in hypertension (LIFE) Study com-
pared the effects the angiotensin receptor blocker (ARB)
losartan with the beta-blocker atenolol on the composite
end-point of cardiovascular death, stroke and myocardial
infarction in patients with hypertension and left ventri-
cular hypertrophy. When the endpoints were evaluated
separately, a relative risk reduction of 25% was found in
fatal and nonfatal stroke, favoring losartan over atenolol
(10).
The perindopril protection against recurrent stroke
study (PROGRESS) was the first trial to be done solely
on patients with diagnosed cerebrovascular disease. Pa-
tients with a history of stroke or TIA were randomized to
placebo, perindopril or perindopril plus indapamide, a
thiazide diuretic. The average blood pressure at entry
was 147/86 mm Hg. The combination of indapamide
and perindopril produced an average reduction in blood
pressure of 12/5 mm Hg and was associated with a 43%
reduction in relative risk of recurrent stroke compared
with perindopril alone, which produced only a 5/3 mm
Hg drop in blood pressure. This study rose the question
what was responsible for the positive results- degree of
reduction in blood pressure or the combination of an
ACEI plus a thiazide (11).
The Study on Cognition and Prognosis in the Elderly
(SCOPE), elderly patients with isolated systolic hyper-
tension were randomized to an ARB-based antihyper-
tensive treatment with candesartan or non-ARB based
treatment (12).
Despite the similar degree of blood pressure lowering
in the ARB arm (22/6 mm Hg) and in the non-ARB arm
(20/5 mm Hg) there was a 42% relative risk reduction in
stroke in the ARB arm. These results suggest that ACEI
and/or ARB, especially in combination with a thiazide
diuretic, may be superior to other anti-hypertensive regi-
mens in the secondary prevention of stroke (confirmed
previous results of PROGRESS).
Three randomized trials of more intensive versus less
intensive blood pressure control have shown that the more
intensive control of blood pressure was superior in re-
ducing the number of strokes, however, these were pri-
marily in diabetic patients and only targeted diastolic
blood pressures- United Kingdom Prospective Diabetes
study (UKPDS) (13).
In The Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial (ALLHAT), a thiazide
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diuretic chlorthalidone was superior to a calcium channel
blocker (CCB) amlodipine, alpha-receptor antagonist
doxazosin, and angiotensin-coverting enzyme inhibitor
(ACEI) lisinopril in preventing one or more major forms
of vascular events including stroke (14).
On Going Telmisartan Alone and in Combination
with Ramipril Global Endpoint Trial (ONTARGET) is
comparing the ACEI ramipril versus the ARB telmisar-
tan versus a combination of both in high-risk patients for
reductions in major vascular events (15).
The European Lacidipine Study on Atherosclerosis
(ELSA) study was evaluating the effects of lacidipine
(calcium antagonist) based treatment and beta-blocker
(atenolol) based treatment on the development and pro-
gression of carotid atherosclerosis (assessed in hyper-
tensive patients). The primary endpoint of this study was
the rate of change in the thickness of the carotid artery
wall, measured with B-mode ultrasound (in patients on
lacidipine IMT was reduced for 40% in 5 year follow up
period) (16).
Valsartan Antihypertensive Long-term Use Evaluation
(VALUE) study. The primary aim of the study was to
determine whether lowering blood pressure with a regi-
men that began with the angiotensin receptor blocker
(ARB) valsartan would provide a 15% risk reduction in
cardiac-related morbidity and mortality when compared
with similar blood pressure control with the calcium
channel blocker (CCB) amlodipine. Stroke was reduced
to a greater degree by amlodipine but not with statistical-
ly significance (17).
Morbidity and Mortality After Stroke, Eprosartan
Compared with Nitrendipine for Secondary Prevention:
principal results of a prospective randomized controlled
study (MOSES) has unequivocally shown that in pa-
tients with a history of cerebrovascular events, a blood
pressure (BP)–lowering treatment based on eprosartan is
more protective against both cerebrovascular event re-
currence and cardiac complications than a treatment
based on nitrendipine (18).
The Secondary Prevention of Small Subcortical Stro-
kes (SPS3) trial which is comparing different antiplatelet
therapies in stroke prevention in patients with lacunar
strokes is also assessing the effects of different blood
pressure targets-systolic blood pressure < 150 mm Hg
versus a target blood pressure < 130 mm Hg (19).
The On Going Telmisartan Alone and in Combina-
tion with Ramipril Global Endpoint Trial (ONTARGET)
is comparing the ACEI ramipril versus the ARB telmi-
sartan versus a combination of both in high-risk patients
for reductions in major vascular events. The Telmisartan
Randomised Assessment Study in ACE-intolerant Sub-
jects with Cardiovascular Disease (TRANSCEND), com-
pares telmisartan 80mg with placebo in ACEI-intolerant
patients with the same risk factors and end-points as
ONTARGET (20).
Effective use of antihypertensive treatments is limited
by lack of awareness of hypertension in patients (prior
studies have shown that only about 60% of hypertensive
individuals were aware of having hypertension), once re-
cognized effective treatment is achieved only in a mino-
rity; one third of hypertensive individuals are controlled
to target blood pressure (mostly due to irregularly drugs
intake).
The guidelines for treatment of hypertension in pre-
vention of stroke state that in primary prevention of
stroke, normal blood pressure limit should be set at a
level lower than 149mmHg/90mmHg and lower than
130mmHg/85mmHg in diabetics. Normal blood pres-
sure values should be reached first with modification of
lifestyle, and if the former is unsuccessful a medical
treatment should be considered. Currently, antihyper-
tensive treatment is recommended for all patients who
have had a TIA or a stroke. The ideal target blood pres-
sure should be individualized according to age, sex and
comorbidities. Benefit has been seen with an average
blood pressure reduction of about 10/5 mm Hg. The
agent of choice depends on individual patient charac-
teristics, but ACEI and ARB in addition to a diuretic
seem to be favorable in patients with stroke, based on
data from the previously mentioned trials (AB/CD rule).
In patients with severe pre-cerebral artery stenosis, inten-
sive blood pressure lowering in the secondary prevention
of stroke should be started with caution, if at all (21).
Hyperlipidemia
Several large randomized trials of statins have demon-
strated reduction of stroke risk associated with lowering
lipid levels. However, observational prospective studies
have not found a consistent relation between cholesterol
levels and incidence of stroke. When evaluating patho-
morphological mechanisms of atherosclerosis, the bene-
ficial effects of statins on stroke risk reduction may be
mediated by additional mechanisms of action such as
improvement of endothelial function (regulation of heart
function, blood pressure, and hyperglycemia), antioxi-
dant properties, inhibition of inflammatory responses,
immunomodulatory actions, and stabilization of athero-
sclerotic lesions. Although the agent used, and the dose
has varied across studies, the results have been consistent,
showing stroke relative risk reduction ranging approxi-
mately from 10 to 50%. Most studies included patients
with concomitant coronary heart disease, therefore it is
not clear enough if the benefit in stroke risk reduction
was due to reduction of myocardial infarction and car-
diac death (22-24).
The Heart Protection Study assessed the efficacy of
simvastatin in patients with coronary disease, other oc-
clusive disease or diabetes and low-density lipoprotein
(LDL) cholesterol levels of at least 3.5mmol/L in reduc-
ing vascular events. A 24% reduction in the rate of all-
-cause mortality, fatal or non-fatal vascular events was
shown in patients treated with simvastatin when com-
pared with those treated with placebo. A 25% reduction
in total stroke incidence rate and a 30% reduction in the
ischemic stroke incidence rate were observed. In the
simvastatin-treated group, transient ischemic attacks were
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significantly less frequent than in the placebo group (2%
versus 2.4%). In this trial, there was no stratification for
past medical events, thus rendering the interpretation of
the effects of simvastatin in subgroups untrustworthy, as
there was a subgroup of patients with the history of CVD
without coronary heart disease. In this subgroup, a 21%
RRR of major vascular events was demonstrated, but no
effect of simvastatin on stroke recurrence was observed
(25).
A few meta-analyses on lipid lowering and ischemic
heart disease prevention have been published in the past
decade. One included all randomized trials that were
published between 1966 and 2001, testing statins, resins,
fibrates, niacin, surgical interventions and diet.49 There
were 10 primary and 28 secondary prevention trials. This
analysis showed a significant 17% RRR of stroke inci-
dence. There was no significant heterogeneity between
trials, either in intervention tested (primary versus se-
condary prevention) or in the type of lipid-lowering the-
rapy examined. When comparing different pharmacolo-
gical agents, only statins yielded a significant 24% RRR of
stroke. When analyzing by type of intervention, the sig-
nificant effect of statins on stroke incidence was present
only in secondary prevention, with a 26% RRR of stroke.
Lipid-lowering therapy, however, did not influence the
incidence of fatal strokes and did not change the in-
cidence of hemorrhagic stroke. A strong evidence for the
role of cholesterol in the pathogenesis of stroke is based
on the correlation of stroke incidence and the degree of
cholesterol reduction, baseline cholesterol level and final
cholesterol level, as the target cholesterol level around
6mmol/L is the divide between absence and presence of
stroke RR (22-24).
Anglo-Scandinavian Cardiac Outcomes Trial–Lipid
Lowering Arm (ASCOT-LLA): Study has showed that
lowering of cholesterol concentrations in individuals at
high risk of cardiovascular disease improves outcome.
Study has assessed benefits of cholesterol lowering in the
primary prevention of coronary heart disease (CHD) in
hypertensive patients who are not conventionally deem-
ed dyslipidemic. 10 305 with non-fasting total cholesterol
concentrations 6·5 mmol/L or less were randomly assign-
ed additional atorvastatin 10 mg or placebo. These pa-
tients formed the lipid-lowering arm of the study. Atorva-
statin lowered total serum cholesterol by about 1.3 mmol/L
compared with placebo at 12 months, and by 1.1 mmol/L
after 3 years of follow-up. The reductions in major car-
diovascular events with atorvastatin are large, given the
short follow-up time (26).
Randomised trial of cholesterol lowering in 4444 pa-
tients with coronary heart disease: the Scandinavian Sim-
vastatin Survival Study (4S): 4444 patients with angina
pectoris or previous myocardial infarction and serum
cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet were
randomized to double-blind treatment with simvastatin
or placebo over the 5.4 years. The 4S study turned out to
be a milestone in cardiology and evidence-based medi-
cine – it was clearly proven that treatment with statins
changed the occurrence of events of patients with coro-
nary heart disease. There was a 24% RRR RRR of stroke
during 6 years follow up period (27).
The Long-Term Intervention with Pravastatin in Ische-
mic Disease (LIPID): In a double-blind, randomized
trial authors compared the effects of pravastatin (40 mg
daily) with those of a placebo over a mean follow-up
period of 6 years (9014 patients). There was a 19% RRR
of stroke in pravastatin group (28).
The Cholesterol and Recurrent Events (CARE) Stu-
dy: 4159 subjects with average total and LDL serum
cholesterol levels (mean, 209 and 139 mg/dL, respecti-
vely) who had sustained an infarction an average of 10
months before study entry and who were randomized to
pravastatin 40 mg/d or placebo. Using prospectively de-
fined criteria, the incidence of stroke, a prespecified se-
condary end point, and transient ischemic attack (TIA)
over a median 5-year follow-up period were assessed.
There was 32% reduction (95% CI, 4% to 52%, P50.03)
in all-cause stroke and 27% reduction in stroke or TIA
(95% CI, 4% to 44%, P50.02) (29).
Stroke Prevention by Aggressive Reduction in Chole-
sterol Levels Study (SPARCL) was the first trial evaluat-
ing patients without concomitant coronary disease. The
trial compared patients assigned to 80 mg of Atorvastatin
daily with recent TIA or stroke (within 6 months of
enrollment) versus placebo group. This study found ab-
solute risk reduction in stroke rates of 2.2% (adjusted HR
0.84; 95% CI 0.71 to 0.99). This was associated with a
reduction of LDL cholesterol levels of 53% (P<0.001).
Although there were more hemorrhagic strokes in the
atorvastatin group (55 versus 33 in the placebo group),
the incidence of fatal hemorrhagic stroke was not signifi-
cantly different between the groups. These results sug-
gesting that use of statins at the time of an ischemic stro-
ke may have beneficial effects (30).
The Northern Manhattan Study found that the 90-day
mortality rate was lower in patients who were taking a
statin compared to those not taking it at the time of stroke
(1.8% vs 10.6%, p = 0.03).
Other studies support the finding of reduced degree of
stroke severity and better outcomes if lipid-lowering agents
were used prior to the vascular event (also when throm-
bolysis was applied). Withdrawal of statin treatment at
the time of an acute ischemic stroke has been related to
poorer neurological outcome at 90 days. The RRR for
stroke in patients on statins was 21% (OR 0.79; 95% CI:
0.73–0.85), the rate of fatal strokes was insignificantly
reduced by 9% (OR 0.91; 0.76–1.10) and there was no
increase in the frequency of hemorrhagic strokes. The
effect of statins was closely linked to LDL-C reduction,
as each 10% reduction in LDL-C reduced the risk of all
strokes by 15.6% (95% CI: 6.7–23.6%).
The Collaborative Atorvastatin Diabetes Study (CARDS)
evaluated the effectiveness of atorvastatin 10mg/day ver-
sus placebo in the primary prevention of coronary artery
disease and stroke in 2,838 patients with type 2 diabetes
without increased cholesterol levels. The RR of stroke was
lowered by 52% in the group treated with atorvastatin
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(RR 48%; 95% CI: 11–69%).52 Cholesterol-lowering the-
rapy is recommended in primary stroke prevention in
high risk patients with coronary artery disease, hyperten-
sion or DM. All patients with a history of ischemic stroke
or TIA may be considered for statin therapy, which may
be started already during the hospitalization (31).
An additive effect of ASA and pravastatin was assessed
in one meta-analysis that included five randomized trials
of secondary prevention with pravastatin 40mg/day and
ASA (73,900 patient years of observation). The RR of
ischemic stroke was reduced by 39% in patients treated
with pravastatin and ASA when compared with placebo.
The combination of pravastatin and ASA was shown to be
more efficient than aspirin and pravastatin alone (RRR
29% and RRR 31%, respectively) (32).
Practice guidelines recommend use of statins for Stro-
ke prevention. The target total cholesterol level should be
below 5,0 mm/L, LDL level varies depending on the
patient’s estimated risk, < 2,59 mmol/L for those with
symptomatic atherosclerotic disease, and < 1,81 mmol/L
for those at very high risk. Very high risk is considered
when there is established cardiovascular disease and one
of the following: multiple major risk factors, poorly con-
trolled risk factors (smoking), the metabolic syndrome
(mainly triglycerides >2,26 mmol/L with low high-den-
sity lipoprotein (HDL) cholesterol <1,03 mmol/L), and
acute coronary syndromes.
Attention should also be paid to HDL levels. Prior
studies in large cohorts have shown an inverse associa-
tion between serum HDL cholesterol and stroke, it is
involved in atherosclerosis and its higher levels have been
related to anti-atherosclerotic and anti-inflammatory pro-
perties in animal and human studies (reduced odds of
having a large-vessel stroke-OR 0.8, 95% CI 0.6 – 1).
Treatment considerations include the addition of niacin
or fibrates in patients with HDL <1.03 mmol/L (22-24).
Hyperglycemia
Diabetes is chronic illness that requires continual me-
dical care and patient self management education in
order to prevent acute complications and to reduce the
risk of long-term complications. According to last diag-
nostic and classification criteria classification of diabetes
includes:
1. Prediabetes:
• Impaired fasting glycemia
• Impaired glucose tolerance
2. Diabetes mellitus type 1
3. Diabetes mellitus type 2
4. Diabetes due to other causes-genetic defects of b
cells, diseases of exocrine pancreas (cystic fibrosis),
drug or chemical-induced
5. Gestational diabetes
Diagnosis of diabetes should be established according
to clinical signs of diabetes and blood tests (Fasting plas-
ma glucose, Glycosylated hemoglobin, Oral glucose tole-
rance test).
Of patients who suffered stroke, a large proportion
either has or is later diagnosed with diabetes (16-24%).
Patients with diabetes are at 1.5-3 times the risk of stroke
compared with general population and associated mor-
tality and morbidity is greater than in those without this
underlying condition. Even patients with metabolic syn-
drome component have a 1.5 fold increased risk of stroke.
This is primarily due to increased proatherogenic risk
factors-abnormal plasma lipid profiles, hypertension, hy-
perglycemia. However, other pathological features as-
sociated with diabetes, such as insulin resistance and
hyperinsulinemia, also lead to atherosclerotic changes in
extracranial and intracranial vessels independently of
glycemia or other attendant risk factors. This is par-
ticularly expressed in smaller cerebral vessels increasing
the incidence of both- overt and silent lacunar infarctions
(1-6).
Generally, vascular complications of diabetes can be
separated into microvascular (diabetic nephropathy, neu-
ropathy and retinopathy) and macrovascular (coronary
disease, cerebrovascular disease, peripheral artery disease)
complications. There are strong evidences of increased
platelet adhesion, hypercoagulability, impaired nitric oxi-
de generation and increased free radical formation as
well as altered calcium regulation in diabetic patients.
Therefore diabetes mellitus can precipitate and fasten
process of atherosclerosis even in younger age. There are
large clinical trials which confirmed these facts even at
early stages of atherosclerosis (subclinical forms). IRAS
(The Insulin Resistance Atherosclerosis study) has shown
that diabetes and glucose intolerance are independent
risk factors connected with increase in intima media
thickness (IMT) (33). SANDS trial (The Stop Athero-
sclerosis in Native Diabetics Study) have shown that
reduction in other cerebrovascular risk factors (hyper-
tension, hyperlipoproteinemia) can slower progression
of IMT thickening in diabetic patients (34). UKPDS
(United Kingdom Prospective Diabetes study) has shown
importance of life style modification and adequate diabe-
tic therapy in stroke risk reduction- reduction of HbA1c
for 1% reduces stroke risk for 4%. Intensive glucose control
(HbA1c=7 mmol/L) with diabetic diet, peroral anti-
diabetic agents or insulin, particularly when instituted
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early in DM, delay or prevents clinically manifest athero-
sclerosis (micro and macro vascular manifestations). STOP
NIDDM trial (Study to Prevent Non-Insulin-Dependent
Diabetes Mellitus)- in diabetic patients taking acarbosa
there was very low stroke incidence (2/682 pts) (35).
Observational study/Diabetes Control and Compli-
cations Intensive insulin treatment reduces any vascular
incident for 41%. PROACTIVE trial (PROspective pio-
glitAzone Clinial Trial in macroVascular Events)- double
blinded randomized study; 5238 pts, 34,5 months, 45 mg
pioglitazon vs placebo). Pioglitazon reduces risk of stro-
ke in type 2 diabetic patients at high risk for stroke (36).
Correction of hypoglycemia was proven as one of the
most important parameters also in therapy of acute stroke.
Meta analyses have shown (32 studies) that hyperglyce-
mia at admission (6-8 mmol/L) is predictor of worse
functional outcome, as well increases 28 days mortality
in previously non diabetic patients (RR 3.1 CI 95% 2.5-3.8)
as well in diabetic patients(RR 1.3 CI 95% 0.5-3.4). Glu-
cose Insulin in stroke Trial-Pilot (GIST), Insulin in Acute
Ischemic stroke (INSULINFARCT), Insulin Resistance
Intervention After Stroke Trial (IRIS) have shown that
there are no differences in acute stroke treatment in
diabetic patients, there is of great importance regulation
of all metabolic parameters as well as blood glucose
concentrations. In trombolysis application there is a
higher risk of bleeding in diabetic patients vs normal
population. About 1/5 of diabetic patients have aspirin
resistance (37-39).
According to the results of all mentioned studies in
this review, hypertension, hypelipidemia and hypergly-
cemia as stroke risk factors are in interactions in the
process of atherosclerosis. Primary as well as secondary
prevention as well as regulating of these risk factors in
acute stroke is of great importance.
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